ArticleThe open cardiovascular medicine journal2016
High-altitude Pulmonary Hypertension: an Update on Disease Pathogenesis and Management.
Article in The open cardiovascular medicine journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 92 citations in OpenAlex.
- Evolution of Exercise Training in Patients with Pulmonary Hypertension-A Comprehensive Review.Healthcare (Basel, Switzerland) · 2026Review
- Effects of Continuous Low-dose Nitric Oxide in a Murine Model of Pulmonary Hypertension with Impaired Lung Development.Anesthesiology · 2026Article
- Multi-Omics Identification of Biomarkers for High-Altitude Pulmonary Hypertension.Journal of cardiovascular development and disease · 2026Article
- Effect of short-term supplemental oxygen therapy on 6-min walk distance in highlanders at risk for pulmonary hypertension: a randomised, crossover trial.ERJ open research · 2026Article
- Right Ventricular Free Wall Strain in Healthy Lowlanders and Highlanders-A Case-Control Study.Journal of clinical medicine · 2026Article
- Altitude hypoxia and hypoxemia: pathogenesis and management.Signal transduction and targeted therapy · 2026Review
- Survival and Hemodynamic Effects of Parenteral Prostanoids in High-Altitude Group 1 Pulmonary Hypertension: A Retrospective Cohort Study.Pulmonary medicine · 2026Article
- Altitude-Related Differences in Biventricular Remodeling and the Clinical Profile of Pulmonary Hypertension: An Exploratory Cardiovascular Magnetic Resonance Study.Journal of the American Heart Association · 2025Article
- Understanding the mechanistic and therapeutic perspectives on cytokines and chemokines in acute high-altitude illness syndromes.Journal of pharmaceutical analysis · 2025Review
- Reduced iron bioavailability drives acute high‑altitude lung injury through HIF1α activation and mitophagy.Molecular medicine reports · 2025Article
- Effects of long-term very high-altitude exposure on cardiopulmonary function of healthy adults in plain areas.Scientific reports · 2025Observational
- A case of plateau heart disease misdiagnosed as chronic pulmonary heart disease.Journal of hypertension · 2025Article
- A Multicenter Study on Mortality and Risk Factors in Patients with Acute Exacerbation of Cor Pulmonale in Plateau of China from 2012 to 2022.Journal of epidemiology and global health · 2025Article
- High-altitude pulmonary hypertension: a comprehensive review of mechanisms and management.Clinical and experimental medicine · 2025Review
- Potential Clinical Impact of Revised Pulmonary Hypertension Definitions at Moderate Altitude.CHEST pulmonary · 2025Article
- Hypoxia as a medicine.Science translational medicine · 2025Review
- Research progress on the regulatory effects and mechanisms of natural active products on intestinal barrier function.Frontiers in pharmacology · 2025Review
- Case Report: High altitude, young lives: unmasking pulmonary hypertension in two unique cases.Frontiers in medicine · 2025Article
- Establishment of mouse models for severe pulmonary hypertension through 'double-hit' strategies.Experimental physiology · 2024Article
- Prevalence of pulmonary hypertension in children with obstructive sleep apnea living at high altitude.Sleep medicine: X · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-altitude pulmonary hypertension (HAPH) affects individuals residing at altitudes of 2,500 meters and higher. Numerous pathogenic variables play a role in disease inception and progression and include low oxygen concentration in inspired air, vasculopathy, and metabolic abnormalities. Since HAPH affects only some people living at high altitude genetic factors play a significant role in its pathogenesis. The clinical presentation of HAPH is nonspecific and includes fatigue, shortness of breath, cognitive deficits, cough, and in advanced cases hepatosplenomegaly and overt right-sided heart failure. A thorough history is important and should include a search for additional risk factors for lung disease and pulmonary hypertension (PH) such as smoking, indoor air pollution, left-sided cardiac disease and sleep disordered breathing. Twelve-lead electrocardiogram, chest X-ray and echocardiography can be used as screening tools. A definitive diagnosis should be made with right-sided heart catheterization using a modified mean pulmonary artery pressure of at least 30 mm Hg, differing from the 25 mm Hg used for other types of PH. Treatment of HAPH includes descent to a lower altitude whenever possible, oxygen therapy and the use of medications such as endothelin receptor antagonists, phosphodiesterase 5 blockers, fasudil and acetazolamide. Some recent evidence suggests that iron supplementation may also be beneficial. However, it is important to note that the scientific literature lacks long-term randomized controlled data on the pharmacologic treatment of HAPH. Thus, an individualized approach to treatment and informing the patients regarding the benefits and risks of the selected treatment regimen are essential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.